LivaNova (NASDAQ:LIVN) Stock Price Expected to Rise, Robert W. Baird Analyst Says

LivaNova (NASDAQ:LIVN) had its target price upped by stock analysts at Robert W. Baird from $66.00 to $72.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 40.82% from the company’s current price.

Other research analysts have also recently issued research reports about the company. Stifel Nicolaus increased their price objective on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 price target on the stock. Finally, Needham & Company LLC upped their price objective on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, LivaNova has an average rating of “Buy” and an average target price of $69.17.

LivaNova Trading Down 0.9 %

NASDAQ LIVN opened at $51.13 on Thursday. The stock has a market cap of $2.78 billion, a PE ratio of 121.74 and a beta of 1.00. LivaNova has a 12 month low of $42.75 and a 12 month high of $64.47. The company’s 50-day moving average price is $51.13 and its 200-day moving average price is $53.12. The company has a current ratio of 3.37, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.15. The business had revenue of $318.60 million for the quarter, compared to the consensus estimate of $305.05 million. LivaNova had a net margin of 1.91% and a return on equity of 13.81%. Equities research analysts forecast that LivaNova will post 2.58 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

A number of hedge funds have recently made changes to their positions in LIVN. Primecap Management Co. CA grew its stake in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock valued at $327,889,000 after purchasing an additional 44,049 shares during the last quarter. Vanguard Group Inc. grew its position in shares of LivaNova by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock worth $102,537,000 after buying an additional 62,480 shares during the last quarter. Point72 Asset Management L.P. grew its position in shares of LivaNova by 204.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock worth $70,479,000 after buying an additional 863,157 shares during the last quarter. Magnetar Financial LLC raised its stake in shares of LivaNova by 8.1% during the 2nd quarter. Magnetar Financial LLC now owns 814,452 shares of the company’s stock worth $44,648,000 after acquiring an additional 61,114 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in LivaNova by 3.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company’s stock valued at $41,889,000 after acquiring an additional 25,277 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.